title: Hyponatremic coma under oxcarbazepine therapy.
abstract: Oxcarbazepine (OXC) is considered to be a promising new antiepileptic drug with similar efficacy and better tolerability compared to carbamazepine (CBZ). However, hyponatremia is supposed to occur even more often than with CBZ. We report on a patient who developed hyponatremic coma under OXC with a serum sodium level of 115 mmol/l, the second published case of OXC-induced hyponatremia with serious clinical adverse effects.
authors.affiliation: Neurologische Klinik, Ludwig-Maximilians-Universität München, Germany.
authors.forename: B J
authors.initials: BJ
authors.lastname: Steinhoff
authors.forename: K D
authors.initials: KD
authors.lastname: Stoll
authors.forename: S R
authors.initials: SR
authors.lastname: Stodieck
authors.forename: W
authors.initials: W
authors.lastname: Paulus
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D002220:Carbamazepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003128:Coma / Q000139:chemically induced*; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced*; D008875:Middle Aged; D000078330:Oxcarbazepine
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine; D000078330:Oxcarbazepine